title: Multiple acquired renal carcinoma tumor capabilities abolished upon silencing of ADAM17.
abstract: Malignancy is a manifestation of acquired defects in regulatory circuits that direct normal cell proliferation and homeostasis. Most of these circuits operate through cell autonomous pathways, whereas others potentially involve the neighboring microenvironment. We report that the metalloprotease ADAM17 plays a pivotal role in several acquired tumor cell capabilities by mediating the availability of soluble transforming growth factor-alpha, an epidermal growth factor receptor (EGFR) ligand, and thus the establishment of a key autocrine signaling pathway. Silencing of ADAM17 in human renal carcinoma cell lines corrects critical features associated with cancer cells, including growth autonomy, tumor inflammation, and tissue invasion. Highly malignant renal carcinoma cancer cells fail to form in vivo tumors in the absence of ADAM17, confirming the essential function of this molecule in tumorigenesis. These data show that ligand shedding is a crucial step in endogenous EGFR activation and endorse prospective therapeutic strategies targeting ADAM17 in human cancer.
authors.affiliation: Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Franovic
authors.forename: Isabelle
authors.initials: I
authors.lastname: Robert
authors.forename: Karlene
authors.initials: K
authors.lastname: Smith
authors.forename: Ghada
authors.initials: G
authors.lastname: Kurban
authors.forename: Arnim
authors.initials: A
authors.lastname: Pause
authors.forename: Lakshman
authors.initials: L
authors.lastname: Gunaratnam
authors.forename: Stephen
authors.initials: S
authors.lastname: Lee
mesh_terms: D051722:ADAM Proteins / Q000172:deficiency* / Q000235:genetics*; D000072198:ADAM17 Protein; D002292:Carcinoma, Renal Cell / Q000235:genetics* / Q000473:pathology / Q000517:prevention & control; D002455:Cell Division; D045744:Cell Line, Tumor; D020868:Gene Silencing; D006801:Humans; D007680:Kidney Neoplasms / Q000235:genetics* / Q000473:pathology / Q000517:prevention & control; D012334:RNA, Neoplasm / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016211:Transforming Growth Factor alpha / Q000502:physiology; D006623:von Hippel-Lindau Disease / Q000235:genetics
chemical_list: D012334:RNA, Neoplasm; D016211:Transforming Growth Factor alpha; D051722:ADAM Proteins; D000072198:ADAM17 Protein; C000606462:ADAM17 protein, human